Literature DB >> 10749109

Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography.

G A Hospers1, A Calogero, A van Waarde, P Doze, W Vaalburg, N H Mulder, E F de Vries.   

Abstract

9-[(1-[18F]Fluoro-3-hydroxy-2-propoxy)methyl]guanine ([18F]FHPG) was evaluated as a tracer for noninvasive positron emission tomography (PET) imaging of herpes simplex virus type 1 thymidine kinase (HSV-tk) gene expression. C6 rat glioma cells with and without the HSV-tk gene were incubated with [18F]FHPG for 2 h. The in vitro tracer uptake in HSV-tk-containing C6tk cells was 35 +/- 5 times higher than that in control cells. In nude rats carrying both a C6 and a C6tk tumor, the average ratio of tracer accumulation between the tumors was 15 +/- 5 at 2 h postinjection. The tracer is rapidly cleared from nontarget tissue into the urine because only the HSV-tk-expressing tumor, kidneys, and bladder remained visible on the late PET images. HPLC analysis revealed that three metabolites, tentatively assigned as FHPG mono-, di-, and triphosphate, were formed in the C6tk tumors only. In conclusion, we have demonstrated that [18F]FHPG is a promising tracer for monitoring HSV-tk enzyme activity in vivo with PET.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749109

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Noninvasive molecular neuroimaging using reporter genes: part II, experimental, current, and future applications.

Authors:  T F Massoud; A Singh; S S Gambhir
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-13       Impact factor: 3.825

2.  [18F]FHPG positron emission tomography for detection of herpes simplex virus (HSV) in experimental HSV encephalitis.

Authors:  A R Buursma; E F J de Vries; J Garssen; D Kegler; A van Waarde; J Schirm; G A P Hospers; N H Mulder; W Vaalburg; H C Klein
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir.

Authors:  Win-Ping Deng; Wen K Yang; Wen-Fu Lai; Ren-Shyan Liu; Jeng-Jong Hwang; Den-Mei Yang; Ying-Kai Fu; Hsin-Ell Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-25       Impact factor: 9.236

Review 4.  PET-based molecular imaging in neuroscience.

Authors:  A H Jacobs; H Li; A Winkeler; R Hilker; C Knoess; A Rüger; N Galldiks; B Schaller; J Sobesky; L Kracht; P Monfared; M Klein; S Vollmar; B Bauer; R Wagner; R Graf; K Wienhard; K Herholz; W D Heiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-23       Impact factor: 9.236

5.  Molecular imaging in oncology.

Authors:  A S K Dzik-Jurasz
Journal:  Cancer Imaging       Date:  2004-10-21       Impact factor: 3.909

6.  Monitoring HSVtk suicide gene therapy: the role of [(18)F]FHPG membrane transport.

Authors:  A R Buursma; I J van Dillen; A van Waarde; W Vaalburg; G A P Hospers; N H Mulder; E F J de Vries
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

7.  Methoxymethyl (MOM) group nitrogen protection of pyrimidines bearing C-6 acyclic side-chains.

Authors:  Tatjana Gazivoda Kraljević; Martina Petrović; Svjetlana Krištafor; Damjan Makuc; Janez Plavec; Tobias L Ross; Simon M Ametamey; Silvana Raić-Malić
Journal:  Molecules       Date:  2011-06-20       Impact factor: 4.411

8.  Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells.

Authors:  Jianhua Gong; Zhongde Wang; Irina Polejaeva; Ravi Salgia; Chien-Min Kao; Chin-Tu Chen; Guangchun Chen; Liaohai Chen
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

9.  Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene.

Authors:  Sea Young Yoon; Carlos Gay-Antaki; Datta E Ponde; Harish Poptani; Charles H Vite; John H Wolfe
Journal:  Mol Ther Methods Clin Dev       Date:  2014-06-04       Impact factor: 5.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.